Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $21.00.

Several equities research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. HC Wainwright reduced their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. UBS Group decreased their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Finally, Citigroup initiated coverage on shares of Telix Pharmaceuticals in a research report on Thursday, September 18th. They set a “buy” rating and a $22.00 price objective on the stock.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TLX. ABC Arbitrage SA purchased a new stake in shares of Telix Pharmaceuticals in the first quarter valued at approximately $451,000. Blair William & Co. IL purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth $297,000. Pier Capital LLC acquired a new position in Telix Pharmaceuticals during the second quarter worth about $3,037,000. Finally, Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the second quarter valued at about $975,000.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX opened at $9.82 on Tuesday. Telix Pharmaceuticals has a 12 month low of $8.76 and a 12 month high of $30.36. The business’s fifty day moving average price is $10.08 and its 200 day moving average price is $12.59.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.